An increasing number of studies demonstrate the potential use of cell-free DNA (cfDNA) as
a surrogate marker for multiple indications in cancer, including diagnosis, prognosis, and …

Since the detection of cell‐free DNA (cfDNA) in human plasma in 1948, it has been investigated
as a non‐invasive screening tool for many diseases, especially solid tumours and foetal …

Through various pathways of cell death, degradation, and regulated extrusion, partial or
complete genomes of various origins (eg, host cells, fetal cells, and infiltrating viruses and …

The most prominent factor that delays the translation of cell-free DNA (cfDNA) analyses to
clinical practice is the lack of knowledge regarding its origin and composition. The elucidation …

Since the discovery of cell-free DNA (cfDNA) in human blood, most studies have focused on
diagnostic and prognostic uses of these markers for solid tumors. Except for some prenatal …

Circulating cell-free DNA (cfDNA) is rapidly transitioning from discovery research to an
important tool in clinical decision making. However, the lack of harmonization of preanalytic …

Body fluids are constantly replenished with a population of genetically diverse cell-free DNA
(cfDNA) fragments, representing a vast reservoir of information reflecting real-time changes …

Cell-free DNA (cfDNA) has become widely recognized as a promising candidate biomarker
for minimally invasive characterization of various genomic disorders and other clinical …

Breast cancer is the most common cancer affecting women worldwide. It is a malignant and
heterogeneous disease with distinct molecular subtypes, which has prognostic and …

Fragments of cell-free DNA (cfDNA) in human body fluids often carry disease-specific alterations
and are now widely recognized as ideal biomarkers for the detection and monitoring of …